Hindustan Bio Sciences Ltd
₹ 7.61
0.00%
04 Mar
3:31 p.m.
About
Incorporated in 2000, Hindustan Biosciences Ltd manufactures & sells pharmaceutical products.[1]
Key Points
- Market Cap ₹ 7.80 Cr.
- Current Price ₹ 7.61
- High / Low ₹ 10.3 / 5.00
- Stock P/E 55.7
- Book Value ₹ 0.84
- Dividend Yield 0.00 %
- ROCE 2.95 %
- ROE 11.8 %
- Face Value ₹ 2.00
Pros
Cons
- Stock is trading at 9.07 times its book value
- Promoter holding is low: 12.2%
- Company has a low return on equity of 5.01% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 198 days.
- Working capital days have increased from 176 days to 442 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Information Technology Information Technology IT - Software Software Products
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.25 | 0.75 | 1.26 | 1.01 | 1.03 | 3.56 | 1.94 | 1.03 | 0.43 | 0.92 | 1.05 | 0.81 | 1.08 | |
| 2.96 | 1.97 | 1.38 | 1.48 | 3.38 | 3.43 | 1.80 | 1.97 | 0.94 | 0.95 | 0.99 | 0.71 | 0.97 | |
| Operating Profit | -0.71 | -1.22 | -0.12 | -0.47 | -2.35 | 0.13 | 0.14 | -0.94 | -0.51 | -0.03 | 0.06 | 0.10 | 0.11 |
| OPM % | -31.56% | -162.67% | -9.52% | -46.53% | -228.16% | 3.65% | 7.22% | -91.26% | -118.60% | -3.26% | 5.71% | 12.35% | 10.19% |
| -0.04 | -0.01 | -1.92 | 0.00 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | |
| Interest | 0.03 | 0.03 | 0.03 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.22 | 0.18 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 |
| Profit before tax | -1.00 | -1.44 | -2.08 | -0.49 | -2.27 | 0.11 | 0.12 | -0.96 | -0.51 | -0.04 | 0.05 | 0.10 | 0.15 |
| Tax % | 0.00% | 0.69% | 0.00% | 0.00% | 0.00% | 0.00% | 33.33% | -2.08% | 0.00% | 0.00% | 0.00% | 0.00% | |
| -0.99 | -1.46 | -2.09 | -0.49 | -2.28 | 0.11 | 0.08 | -0.94 | -0.52 | -0.04 | 0.06 | 0.10 | 0.14 | |
| EPS in Rs | -0.97 | -1.42 | -2.04 | -0.48 | -2.22 | 0.11 | 0.08 | -0.92 | -0.51 | -0.04 | 0.06 | 0.10 | 0.14 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -16% |
| 3 Years: | 24% |
| TTM: | -11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 5% |
| 3 Years: | 30% |
| TTM: | -13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 21% |
| 3 Years: | 13% |
| 1 Year: | 9% |
| Return on Equity | |
|---|---|
| 10 Years: | -18% |
| 5 Years: | -26% |
| 3 Years: | 5% |
| Last Year: | 12% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 2.05 | 2.05 | 2.05 | 2.05 |
| Reserves | -1.83 | -3.34 | -5.43 | -5.92 | -8.20 | -8.09 | -8.01 | -8.95 | -9.46 | -1.30 | -1.25 | -1.15 | -1.19 |
| 0.77 | 0.97 | 0.94 | 1.30 | 1.57 | 3.37 | 2.60 | 1.86 | 2.17 | 2.46 | 2.56 | 2.51 | 2.62 | |
| 0.48 | 0.17 | 0.12 | 0.24 | 0.09 | 0.10 | 0.71 | 0.32 | 0.02 | 0.08 | 0.01 | 0.01 | 0.02 | |
| Total Liabilities | 9.67 | 8.05 | 5.88 | 5.87 | 3.71 | 5.63 | 5.55 | 3.48 | 2.98 | 3.29 | 3.37 | 3.42 | 3.50 |
| 0.16 | 0.08 | 0.07 | 0.06 | 0.06 | 0.06 | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.44 | |
| CWIP | 1.92 | 1.92 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 7.59 | 6.05 | 5.81 | 5.81 | 3.65 | 5.57 | 5.50 | 3.44 | 2.94 | 3.26 | 3.34 | 3.39 | 3.06 | |
| Total Assets | 9.67 | 8.05 | 5.88 | 5.87 | 3.71 | 5.63 | 5.55 | 3.48 | 2.98 | 3.29 | 3.37 | 3.42 | 3.50 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.46 | -0.27 | 0.46 | -0.16 | -0.23 | -1.32 | 0.82 | 0.75 | -0.34 | -0.05 | -1.41 | 0.03 | |
| 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.51 | 0.30 | -0.63 | 0.18 | 0.21 | 1.50 | -0.81 | -0.93 | 0.34 | 0.05 | 1.43 | -0.05 | |
| Net Cash Flow | 0.09 | 0.03 | -0.17 | 0.01 | -0.02 | 0.17 | 0.01 | -0.18 | -0.01 | 0.00 | 0.03 | -0.02 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 202.78 | 155.73 | 136.15 | 169.85 | 113.40 | 171.22 | 255.88 | 219.71 | 118.84 | 178.53 | 152.95 | 198.27 |
| Inventory Days | 36.08 | 25.08 | 0.00 | 0.00 | 51.23 | 13.89 | 95.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days Payable | 84.88 | 39.01 | 44.82 | 7.58 | 185.31 | |||||||
| Cash Conversion Cycle | 153.97 | 141.80 | 136.15 | 169.85 | 119.80 | 177.54 | 166.03 | 219.71 | 118.84 | 178.53 | 152.95 | 198.27 |
| Working Capital Days | 186.56 | 111.93 | -63.73 | -191.53 | -170.10 | 85.10 | 86.55 | -148.83 | -500.81 | -226.14 | 312.86 | 441.60 |
| ROCE % | -9.91% | -16.40% | -1.91% | -8.43% | -49.08% | 2.62% | 2.51% | -23.75% | -16.67% | -1.30% | 1.52% | 2.95% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Foreign Exchange Earnings INR Lakhs |
|
||||||||||
| Revenue from Operations INR Lakhs |
|||||||||||
| Number of Employees Absolute |
|||||||||||
| Relative Quantity Performance (Erythropoietin) Percentage of Previous Year |
|||||||||||
Requires Premium
Requires Premium
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2 Feb - Newspaper Advertisement in Hitech Edition (English Language) and Prajapalana (Telugu Language) regarding Unaudited Standalone financial results for the Third Quarter ended on December 31, 2025
- Un-Audited Results For Quarter Ended 31-12-2025 31 Jan
-
Board Meeting Outcome for Outcome Of Board Meeting
31 Jan - Board approved unaudited financial results for quarter ended 31 Dec 2025; limited review report enclosed.
- Revised Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 24 Jan
-
Announcement under Regulation 30 (LODR)-Acquisition
23 Jan - 22-01-2026: Bosco Armando bought 15,000 shares; combined holding 525,000 (5.12% of equity).
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
HBSL previously sourced bulk drugs (APIs) and drug intermediates and holds an import license from GEAC for Recombinant Human Erythropoietin, following clinical trials. It now manufactures and markets a wide range of premium finished dosage forms in pharmaceutical and biotechnology segments.